Epilepsy Clinical Trial
— EpiDFAOfficial title:
Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana
NCT number | NCT05246566 |
Other study ID # | 21_RIPH3-05 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 15, 2022 |
Est. completion date | April 30, 2024 |
The justification of this prospective and multicenter study is based on the absence of published data concerning, status epilepticus (SE), a pathology which seems frequent in the French West Indies (FWI) and French Guiana, and whose etiological and prognostic characteristics are often mentioned or assumed but which remain to be demonstrated. The scientific interest lies both in the knowledge of the epidemiology of this pathology and in the identification of the main etiologies, in particular the underlying brain lesions. The morbidity of SE is significant, associating neurological disorders with impaired consciousness, respiratory, hemodynamic and cardiac rhythm disorders, as well as metabolic disorders such as acidosis. SE-related mortality in the acute phase ranges from 3-40% across studies and regions, while long-term mortality ranges from 17-80% depending on age, cause of SE, comorbidities and the occurrence of complications. The prognosis of this pathology has however improved in recent years in developed countries or countries with a high level of health system. On the other hand, the morbidity and mortality of SE in the French overseas departments is not known, even if these territories are supposed to be at an equivalent level in terms of health system to that of mainland France.
Status | Recruiting |
Enrollment | 241 |
Est. completion date | April 30, 2024 |
Est. primary completion date | January 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (= 18 years old) treated for SE by SAMU/SMUR and by emergencies or intensive care in the French West Indies and French Guiana. - Covered for suspected or SE diagnosis defined by one of the following: - a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis. - a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (= 2) at short intervals without recovery of interictal consciousness. - a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes. - an absence-type crisis that lasts longer than 10 to 15 minutes. - a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes. - a coma with an epileptic cause diagnosed on an EEG. - Patient if he is able to, or representative of the patient in case of incapacity, having given his agreement for the use of his medical data for this research. Exclusion Criteria: - Age < 18 years old - Absence of consent from the patient, or representative to the use of the data for the research. - Patient whose main residence is not in the department where the study is taking place (vacationer for example). |
Country | Name | City | State |
---|---|---|---|
France | Hospital of Basse-Terre | Basse-Terre | Guadeloupe |
France | Hospital of Cayenne | Cayenne | French Guiana |
France | University Hospital Center of Martinique | Fort-de-France | Martinique |
France | University Hospital Center of Guadeloupe | Pointe-à-Pitre | Guadeloupe |
Lead Sponsor | Collaborator |
---|---|
University Hospital Center of Martinique |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To describe the neurological evolution 30 days and 90 days after the SE eoisode in adults in the French West Indies and French Guiana. | Number and percentage of patients with an unfavorable neurological evolution according to an assessment using the Modified Rankin Scale (MRS greater than 2) in the adult SE population at day 30 and day 90. | 15 months | |
Other | To measure the mortality rate at day 1, day 30 and day 90 after the onset of SE in adults treated by SAMU/SMUR and emergency services in the French West Indies and French Guiana. | Mortality rate in the adult SE population included in the study on day 1, day 30 and day 90. | 15 months | |
Primary | To measure the annual incidence rate of occurrence of status epilepticus (SE) in adults treated by SAMU/SMUR and emergency services in the French West Indies and French Guiana. | The incidence rate of the occurrence of SE expressed per 100,000 person-years.This incidence rate will be calculated by dividing the number of new cases of SE during the 12 months of the inclusion phase of the study by the estimate of the average number of inhabitants aged 18 and over in each region of inclusion. | 15 months | |
Secondary | To describe the epidemiological characteristics of status epilepticus in adults in the French West Indies and French Guiana in terms of patient profiles, associated factors, recurrences, causes and complications. | Characteristics of the patients (age, sex) / Number and percentage of patients with factors associated with SE (alcoholism, drug addiction, precarity, etc.) / Number and percentage of recurrences of SE episodes (antecedent of SE) / Number and percentage of the different causes causing a SE episode / Number and percentage of the different complications during the occurrence of a SE episode. | 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |